BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Prophylaxis Versus On-demand Therapy Through Economic Report
Completed
- Conditions
- Hemophilia A
- Interventions
- Drug: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
- First Posted Date
- 2010-07-09
- Last Posted Date
- 2011-04-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 58
- Registration Number
- NCT01159587
Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis
Completed
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Drug: BAY86-5046_Interferon-beta-1b
- First Posted Date
- 2010-07-08
- Last Posted Date
- 2010-07-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 226
- Registration Number
- NCT01158183
Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects
Phase 1
Completed
- Conditions
- PediatricsVenous Thrombosis
- Interventions
- First Posted Date
- 2010-06-17
- Last Posted Date
- 2015-08-06
- Lead Sponsor
- Bayer
- Target Recruit Count
- 59
- Registration Number
- NCT01145859
Evaluate Analgesic Efficacy of Fast Release Aspirin
Phase 3
Completed
- Conditions
- Drugs, Investigational
- Interventions
- Drug: Acetylsalicyclic acid (Aspirin, BAYE4465)Drug: Acetylsalicyclic acid (Fast acting Aspirin, BAY1019036)Drug: Placebo
- First Posted Date
- 2010-05-13
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 500
- Registration Number
- NCT01122602
Treatment of Hypertension With Adalat® in Combination With Other Drugs
- First Posted Date
- 2010-05-06
- Last Posted Date
- 2012-06-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 4497
- Registration Number
- NCT01118286
Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine
Phase 4
Completed
- Conditions
- Sleep
- Interventions
- First Posted Date
- 2010-05-06
- Last Posted Date
- 2015-06-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 162
- Registration Number
- NCT01118273
Evaluate Analgesic Efficacy of Fast Release Aspirin
Phase 3
Completed
- Conditions
- Drugs, Investigational
- Interventions
- Drug: Acetylsalicylic acid (Fast release Aspirin, BAY1019036)Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)Drug: Placebo
- First Posted Date
- 2010-05-05
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 514
- Registration Number
- NCT01117636
Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies
Phase 1
Completed
- Conditions
- Neoplasm
- First Posted Date
- 2010-05-05
- Last Posted Date
- 2015-11-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 86
- Registration Number
- NCT01117623
Multiple Dose Escalation Study (14 Days) to Investigate Safety, Tolerability, PK and PD of Vardenafil and BAY60-4552
Phase 1
Completed
- Conditions
- Erectile Dysfunction
- Interventions
- Drug: BAY60-4552 + VardenafilDrug: Placebo
- First Posted Date
- 2010-04-26
- Last Posted Date
- 2013-02-22
- Lead Sponsor
- Bayer
- Target Recruit Count
- 37
- Registration Number
- NCT01110590
Study in Chronic Kidney Disease (CKD) Not on Dialysis
Phase 3
Completed
- Conditions
- Hyperphosphatemia
- Interventions
- Drug: PlaceboDrug: Fosrenol (Lanthanum Carbonate, BAY77-1931)
- First Posted Date
- 2010-04-26
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 143
- Registration Number
- NCT01110629
© Copyright 2025. All Rights Reserved by MedPath